CureVac N.V. logo
CureVac N.V. CVAC

Quarterly report 2022-Q2
added 08-18-2022

report update icon

CureVac N.V. Deferred Revenue 2011-2026 | CVAC

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.
Features of the metric
  • Sources of future cash inflows
    A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
  • Assessment of operational stability
    Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
  • Risks and obligations
    Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
  • Analysis of liquidity and cash flow
    Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
  • Impact on company valuation
    In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue CureVac N.V.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- 158 M 7.48 M 5.78 M - - - - - - -

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
158 M 5.78 M 57.1 M

Deferred Revenue of other stocks in the Biotechnology industry

Issuer Deferred Revenue Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
86.5 M - 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
283 K - -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
563 K - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
15.9 M - - $ 40.3 B usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
1.96 M $ 1.63 -4.4 % $ 191 M usaUSA
Genfit SA Genfit SA
GNFT
124 K - 2.54 % $ 160 B franceFrance
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
2.69 M - -1.52 % $ 24.7 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
8.25 M $ 7.83 -5.21 % $ 214 M israelIsrael
Esperion Therapeutics Esperion Therapeutics
ESPR
34.5 M $ 3.12 - $ 649 M usaUSA
Exelixis Exelixis
EXEL
1.12 M $ 51.1 -0.37 % $ 13.9 B usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
2.34 M $ 8.9 0.56 % $ 1.08 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
13.5 M $ 4.4 -7.76 % $ 1.31 B canadaCanada
Midatech Pharma plc Midatech Pharma plc
MTP
1.3 M - -18.52 % $ 27.3 M britainBritain
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
643 K $ 17.3 -5.57 % $ 809 M usaUSA
BioNTech SE BioNTech SE
BNTX
300 M $ 91.99 -0.26 % $ 22.2 B germanyGermany
Compugen Ltd. Compugen Ltd.
CGEN
11 M $ 3.03 6.32 % $ 283 M israelIsrael
Gilead Sciences Gilead Sciences
GILD
202 M $ 132.06 -0.74 % $ 164 B usaUSA
Genmab A/S Genmab A/S
GMAB
26 M $ 26.9 1.32 % $ 1.74 B danmarkDanmark
Advaxis Advaxis
ADXS
165 K - -9.65 % $ 45.9 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
405 K $ 3.49 -4.12 % $ 5.75 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
2.19 M - 5.93 % $ 314 M canadaCanada
Grifols, S.A. Grifols, S.A.
GRFS
30.1 M $ 7.79 1.04 % $ 5.29 B spainSpain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
517 K - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
6.3 M - - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
957 K - 1.93 % $ 17.4 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
728 K $ 2.3 3.14 % $ 64.2 M usaUSA
AlloVir AlloVir
ALVR
2.66 M - 4.14 % $ 49.1 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
248 K $ 9.24 36.48 % $ 264 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
85.7 K - -11.43 % $ 502 K usaUSA